Systems genetics identifies a role for Cacna2d1 regulation in elevated intraocular pressure and glaucoma susceptibility

Sumana R. Chintalapudi, Doaa Nabih Maria, Xiang Di Wang, Jessica N. Cooke Bailey, Rand Allingham, Murray H. Brilliant, Donald L. Budenz, John H. Fingert, Douglas Gaasterland, Teresa Gaasterland, Jonathan L. Haines, Lisa Hark, Michael A. Hauser, Rob P. Igo, Jae H. Kang, Peter Kraft, Richard Lee, Paul R. Lichter, Yutao Liu, Sayoko E. Moroi, Louis R. Pasquale, Margaret A. Pericak‐Vance, Anthony Realini, Doug Rhee, Julia R. Richards, Robert Ritch, Joel S. Schuman, William K. Scott, Kuldev Singh, Arthur J. Sit, Douglas Vollrath, Gadi Wollstein, Donald J. Zack, Tin Aung, Peter Bonnemaijer, Cheng-Yu Cheng, Jamie E. Craig, Cornelia M. van Duijn, Puya Gharahkhani, Adriana Iglesias González, Christopher J. Hammond, Alex W. Hewitt, René Hoehn, Fridbert Jonansson, Anthony P. Khawaja, Chiea Chuen Khor, Caroline C. W. Klaver, Andrew Lotery, David A. Mackey, Stuart MacGregor, Calvin C P Pang, Francesca Pasutto, Kāri Stefánsson, Guðmar Þorleifsson, Unnar Thorsteinsdottir, Véronique Vitart, Eranga N. Vithana, Terri L. Young, Tanja Zeller, Pirro G. Hysi, Janey L. Wiggs, Robert W. Williams, Monica M. JablonskiNature Communications 2017 · DOI

TL;DR

This study leverages systems genetics in mice to identify Cacna2d1 as a key gene regulating intraocular pressure (IOP), a major risk factor for glaucoma. They demonstrate that a drug targeting the CACNA2D1 protein, pregabalin, effectively lowers IOP, with its efficacy dependent on the Cacna2d1 genetic makeup. This work highlights a promising therapeutic avenue and validates a powerful approach for discovering disease-related genes and drug targets.

What Problem Does This Paper Address?

Glaucoma is a leading cause of blindness, and elevated intraocular pressure (IOP) is its primary modifiable risk factor. While current treatments aim to lower IOP, they don't address the underlying genetic and molecular mechanisms that contribute to its variability. Understanding these mechanisms is crucial for developing more effective therapies and personalized treatment strategies. The heritability of IOP is significant (~55% in humans), indicating a strong genetic component, but the specific genes and pathways involved are not fully understood. This paper aims to bridge this knowledge gap by identifying novel genetic regulators of IOP and exploring their therapeutic potential.

Methods

The researchers employed a "systems genetics" approach, which integrates genetic information with phenotypic data across a genetically diverse population. Specifically, they utilized the BXD mouse family, a well-characterized resource derived from crossing C57BL/6J and DBA/2J strains. This cross generates strains with unique combinations of genetic variants, allowing for the mapping of quantitative trait loci (QTLs) associated with complex traits like IOP.

Their workflow involved:

  • Quantitative Trait Locus (QTL) Mapping: Measuring IOP across a large number of BXD strains to identify genomic regions significantly associated with IOP variation.
  • Stringent Candidate Gene Selection: Employing a multi-step refinement process that included:
  • Expression QTL (eQTL) mapping: Identifying genes whose expression levels are genetically controlled.
  • Correlation analyses: Examining the relationship between gene expression and IOP.
  • Sequence variant analysis: Identifying genetic differences between parental strains within candidate regions.
  • Functional and biological relevance: Prioritizing genes expressed in ocular tissues and known to be involved in relevant pathways.
  • Human GWAS Data Integration: Validating candidate genes by searching for associations with human POAG and IOP in existing genome-wide association studies (GWAS).
  • Pharmacological Intervention: Testing the effect of pregabalin, a drug known to target CACNA2D1, on IOP in different mouse strains and in rabbits.

Datasets

The primary dataset used was generated by the researchers themselves, involving IOP measurements from 65 BXD mouse strains. Additionally, they utilized publicly available gene expression data from the BXD family (available on GeneNetwork) and human GWAS data from the NEIGHBORHOOD consortium for validation.

Key Insights and Ideas

  • The BXD family as a powerful tool: This study reinforces the utility of the BXD mouse family for dissecting the genetic architecture of complex traits like IOP, demonstrating its ability to uncover novel candidate genes.
  • CACNA2D1 as a critical IOP regulator: The identification of Cacna2d1 as a top candidate gene, supported by multiple lines of evidence, is a significant finding. Its role in modulating IOP suggests it's a key player in the complex network controlling this crucial ocular parameter.
  • Haplotype-specific drug response: The finding that the IOP-lowering effect of pregabalin is dependent on the Cacna2d1 haplotype is particularly exciting. This suggests that genetic background can influence drug efficacy, paving the way for personalized medicine approaches in glaucoma treatment.
  • Bridging mouse and human genetics: The successful integration of mouse systems genetics with human GWAS data highlights the power of this translational approach for identifying and validating disease-relevant genes.

Key Results

  • A significant QTL for IOP was mapped to a narrow locus on mouse chromosome 5.
  • Cacna2d1 emerged as the strongest positional candidate gene within this QTL, fulfilling stringent selection criteria.
  • Cacna2d1 expression in the eye was significantly influenced by the parental allele (haplotype), with strains carrying the B allele showing higher expression.
  • Older mice with the B allele of Cacna2d1 exhibited significantly higher IOP compared to those with the D allele.
  • Human GWAS data showed nominal association between a CACNA2D1 SNP and primary open-angle glaucoma (POAG).
  • Topical application of pregabalin significantly reduced IOP in mice in a dose-dependent manner.
  • The IOP-lowering effect of pregabalin was haplotype-specific, with mice carrying the B allele of Cacna2d1 showing a more pronounced response.
  • CACNA2D1 was localized to key ocular tissues involved in aqueous humor dynamics, including the trabecular meshwork (TM) and ciliary body (CB), in both mice and humans.

Limitations and Future Work

The authors acknowledge that while they found nominal association for CACNA2D1 SNPs in human GWAS data, further validation in larger, diverse cohorts is warranted. They also propose a model for how pregabalin might reduce IOP by influencing aqueous humor production and outflow, but further studies are needed to confirm these specific mechanisms. Future work could focus on:

  • Investigating the precise molecular mechanisms by which Cacna2d1 regulates IOP.
  • Exploring the therapeutic potential of pregabalin and other CACNA2D1 modulators in preclinical glaucoma models and human clinical trials.
  • Expanding the systems genetics approach to identify other genes and pathways involved in IOP regulation and glaucoma susceptibility.
  • Developing predictive models for drug response based on CACNA2D1 haplotype.

Summary updated

Abstract

Glaucoma is a multi-factorial blinding disease in which genetic factors play an important role. Elevated intraocular pressure is a highly heritable risk factor for primary open angle glaucoma and currently the only target for glaucoma therapy. Our study helps to better understand underlying genetic and molecular mechanisms that regulate intraocular pressure, and identifies a new candidate gene, Cacna2d1, that modulates intraocular pressure and a promising therapeutic, pregabalin, which binds to CACNA2D1 protein and lowers intraocular pressure significantly. Because our study utilizes a genetically diverse population of mice with known sequence variants, we are able to determine that the intraocular pressure-lowering effect of pregabalin is dependent on the Cacna2d1 haplotype. Using human genome-wide association study (GWAS) data, evidence for association of a CACNA2D1 single-nucleotide polymorphism and primary open angle glaucoma is found. Importantly, these results demonstrate that our systems genetics approach represents an efficient method to identify genetic variation that can guide the selection of therapeutic targets.
BibTeX
@inproceedings{chintalapudi2017systems,
  author = {Sumana R. Chintalapudi and Doaa Nabih Maria and Xiang Di Wang and Jessica N. Cooke Bailey and Rand Allingham and Murray H. Brilliant and Donald L. Budenz and John H. Fingert and Douglas Gaasterland and Teresa Gaasterland and Jonathan L. Haines and Lisa Hark and Michael A. Hauser and Rob P. Igo and Jae H. Kang and Peter Kraft and Richard Lee and Paul R. Lichter and Yutao Liu and Sayoko E. Moroi and Louis R. Pasquale and Margaret A. Pericak‐Vance and Anthony Realini and Doug Rhee and Julia R. Richards and Robert Ritch and Joel S. Schuman and William K. Scott and Kuldev Singh and Arthur J. Sit and Douglas Vollrath and Gadi Wollstein and Donald J. Zack and Tin Aung and Peter Bonnemaijer and Cheng-Yu Cheng and Jamie E. Craig and Cornelia M. van Duijn and Puya Gharahkhani and Adriana Iglesias González and Christopher J. Hammond and Alex W. Hewitt and René Hoehn and Fridbert Jonansson and Anthony P. Khawaja and Chiea Chuen Khor and Caroline C. W. Klaver and Andrew Lotery and David A. Mackey and Stuart MacGregor and Calvin C P Pang and Francesca Pasutto and Kāri Stefánsson and Guðmar Þorleifsson and Unnar Thorsteinsdottir and Véronique Vitart and Eranga N. Vithana and Terri L. Young and Tanja Zeller and Pirro G. Hysi and Janey L. Wiggs and Robert W. Williams and Monica M. Jablonski},
  title = {{Systems genetics identifies a role for Cacna2d1 regulation in elevated intraocular pressure and glaucoma susceptibility}},
  booktitle = {Nature Communications},
  year = {2017},
  doi = {10.1038/s41467-017-00837-5},
}
Figure